HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oral versus intravenous paracetamol: which is better in closure of patent ductus arteriosus in very low birth weight infants?

AbstractOBJECTIVES:
To compare the efficacy of oral and intravenous paracetamol for closure of hemodynamically significant patent ductus arteriosus (HSPDA) in very low birth weight (VLBW) preterm infants.
METHODS:
Eighteen VLBW infants with HSPDA treated with either intravenous (n = 10) or oral (n = 8) paracetamol at 60 mg/kg/d for three consecutive days were analysed retrospectively. Ductal closure rate and evaluation of liver function tests were the major outcomes.
RESULTS:
After two courses of treatment, HSPDA closure rate was higher in oral paracetamol group than that in the intravenous paracetamol group (88% versus 70%), but it was not statistically significant (p = 0.588). Liver function tests were normal after the treatment.
CONCLUSION:
Although it was not statistically significant, the cumulative closure rates were higher in oral paracetamol group than those in the intravenous group. Larger trials are needed to confirm these data.
AuthorsSelim Sancak, Tulin Gokmen Yildirim, Sevilay Topcuoglu, Taner Yavuz, Guner Karatekin, Fahri Ovali
JournalThe journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (J Matern Fetal Neonatal Med) Vol. 29 Issue 1 Pg. 135-9 ( 2016) ISSN: 1476-4954 [Electronic] England
PMID25471090 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Analgesics, Non-Narcotic
  • Acetaminophen
Topics
  • Acetaminophen (administration & dosage)
  • Administration, Intravenous
  • Administration, Oral
  • Analgesics, Non-Narcotic (administration & dosage)
  • Ductus Arteriosus, Patent (drug therapy)
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Very Low Birth Weight
  • Male
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: